Molecular mechanism of action for reversible P2Y12 antagonists

被引:9
|
作者
Liu, Haibo [2 ]
Ge, Hu [1 ]
Peng, Yong [2 ]
Xiao, Peigen [2 ]
Xu, Jun [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Plant Dev, Beijing 100194, Peoples R China
关键词
P2Y(12) receptor; ADP; Antagonists; Platelets aggregation; SWISS-MODEL REPOSITORY; CLOPIDOGREL PLUS ASPIRIN; ANTIPLATELET THERAPY; RECEPTOR ANTAGONIST; COST-EFFECTIVENESS; P2; RECEPTORS; FREE-ENERGY; PROTEIN; PREVENTION; P2Y12;
D O I
10.1016/j.bpc.2011.03.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, reversible antagonists of the P2Y(12) receptor have been reported. However, the mechanisms of binding have not been elucidated. To this end, a number of homology models were built by means of three programs from four templates. A consensus model was derived from those initial models. The final model was created by refining the consensus model with molecular dynamics simulations. The agonist and antagonists of P2Y(12) have been docked in the final model. For the agonist, the Arg256, Lys280, and Phe252 are "hot" residues. For the antagonists, the Lys280 and Phe252 are "hot" residues that have hydrogen bonding contacts and pi-pi interactions, respectively. These results can explain the observations of mutation experiments and can guide the design of new inhibitors. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:74 / 81
页数:8
相关论文
共 50 条
  • [21] State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists
    Zetterberg, Fredrik
    Svensson, Peder
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (12) : 2739 - 2754
  • [22] Thrombus remodelling by reversible and irreversible P2Y12 inhibitors
    Tunstromer, Kjersti
    Faxalv, Lars
    Larsson, Pia
    Lindahl, Tomas L.
    Boknas, Niklas
    PLATELETS, 2023, 34 (01)
  • [23] Ticagrelor: the first novel reversible P2Y12 inhibitor
    Htun, Wah Wah
    Steinhubl, Steven R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (02) : 237 - 245
  • [24] Reversible, orally available ADP receptor (P2Y12) antagonists Part I: Hit to lead process
    Islam, Imadul
    Yuan, Shendong
    Wei, Robert G.
    Xu, Wei
    Morrissey, Michael
    Mohan, Raju
    Zheng, Dewan
    Dimella, Andrea
    Dunning, Laura
    Snider, Michael
    Subramanyam, Babu
    Tseng, Jih-Lie
    Bryant, Judi A.
    Buckman, Brad O.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (09) : 1459 - 1463
  • [25] Switching between P2Y12 antagonists - From bench to bedside
    Gasecka, Aleksandra
    Konwerskia, Michal
    Pordzik, Justyna
    Soplinska, Aleksandra
    Filipiak, Krzysztof J.
    Siller-Matula, Jolanta M.
    Postula, Marek
    VASCULAR PHARMACOLOGY, 2019, 115 : 1 - 12
  • [26] Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists
    Uta Schilling
    Jasper Dingemanse
    Mike Ufer
    Clinical Pharmacokinetics, 2020, 59 : 545 - 566
  • [27] Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists
    Richard C. Becker
    Journal of Thrombosis and Thrombolysis, 2009, 28 : 513 - 514
  • [28] Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists
    Becker, Richard C.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2009, 28 (04) : 513 - 514
  • [29] Course of platelet miRNAs after cessation of P2Y12 antagonists
    Jaeger, Bernhard
    Stojkovic, Stefan
    Haller, Paul M.
    Piackova, Edith
    Kahl, Beatrice S.
    Andric, Tijana
    Vargas, Kris G.
    Wojta, Johann
    Huber, Kurt
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2019, 49 (08)
  • [30] What is the best dose of aspirin in association with P2Y12 antagonists?
    Cattaneo, Marco
    HEART, 2011, 97 (03) : 263 - 264